by Margy MacMillan
With the United States marking its 250th anniversary this month, I find myself reflecting on this incredible milestone and, similarly, the history of ASTCT and the field we represent. While our...
by Nature Medicine
Findings from a Phase II study suggest that ciltacabtagene autoleucel (cilta-cel), which is thought to be more effective when delivered in earlier disease states, has promise in the setting of...
by Transplantation and Cellular Therapy
Post-transplantation cyclophosphamide (PTCy) is gaining traction as standard prevention against graft-versus-host disease (GVHD) following allogeneic hematopoietic cell transplantation (HCT), but...
by Frontiers in Immunology
Irradiating tumors before administering chimeric antigen receptor (CAR) T-cell therapy may boost CAR T-cell infiltration and improve efficacy in solid tumors, researchers report.
by Cancer Discovery
Scientists have developed a construct that they say overcomes challenges specific to using chimeric antigen receptor (CAR)-T cells to treat individuals with acute myeloid leukemia (AML).
by Eneida R. Nemecek
Explore ASTCT’s Board Member Spotlight featuring Dr. Eneida Nemecek, a leader in pediatric blood and marrow transplantation and cellular therapy at OHSU. She shares insights on her clinical...